| Abstrakt: |
A recent study conducted by researchers at Harvard Medical School has found a potential association between the use of semaglutide, a medication for type 2 diabetes, and an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a condition that can cause vision loss. The study analyzed data from a registry of patients with type 2 diabetes or overweight/obesity who were prescribed semaglutide or other medications. The results showed a higher incidence of NAION in patients prescribed semaglutide compared to those prescribed other medications. However, as this was an observational study, further research is needed to establish causality. [Extracted from the article] |
